Vaccines

US Infectious Disease Physicians Predict a COVID-19 Vaccine by May 2021, According to InCrowd Data

Retrieved on: 
Tuesday, November 17, 2020
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Science, Practice Management, Research, Managed care, Infectious diseases, General Health, Hospitals, Science, Clinical trials, Medicine, Medical research, Health sciences, Life sciences, Vaccines, COVID-19 vaccine, Vaccine, Vaccination, Coronavirus disease, Human challenge study

The US healthcare system is relying on physicians to inform and engage patients on COVID-19 vaccination, and these physicians are keenly monitoring vaccine development efforts.

Key Points: 
  • The US healthcare system is relying on physicians to inform and engage patients on COVID-19 vaccination, and these physicians are keenly monitoring vaccine development efforts.
  • InCrowd is continually monitoring the sentiment of physicians like these as part of our mission to ensure that healthcare professionals are heard.
  • Yet less than halfjust 47%of US infectious disease specialists feel highly confident in prescribing an FDA-approved COVID-19 vaccine.
  • InCrowds Wave 2 of its Novel Coronavirus (COVID-19) Vaccine Development report included n=100 US infectious disease physicians responding to a 12-minute MicroSurvey between October 22-26, 2020.

European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

Retrieved on: 
Tuesday, November 17, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Life sciences, Branches of biology, Medical research, Biotechnology, Vaccines, Moderna, Messenger RNA, European Medicines Agency, COVID-19 vaccine

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Companys vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.

Key Points: 
  • Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Companys vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.
  • The start of the rolling review process marks an important next step as we continue to advance mRNA-1273 in collaboration with European regulatory authorities, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We will continue our ongoing dialogue with the EMA as we seek to develop a safe and effective vaccine.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

Retrieved on: 
Tuesday, November 17, 2020
Health, FDA, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical research, Health sciences, Medicine, Health, Vaccines, Moderna, COVID-19 vaccine, Department of Health and Social Care, MHRA, Medicines and Healthcare products Regulatory Agency, the Phase 3 COVE Study, mRNA-1273

This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines.

Key Points: 
  • This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines.
  • We appreciate the collaboration with the UK Government as with many other governments and other key partners around the world, said Stphane Bancel, CEO of Moderna.
  • On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273.
  • This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna.

Crane Worldwide strengthens its global solutions for the safe delivery of the COVID-19 vaccine

Retrieved on: 
Tuesday, November 17, 2020
Vaccination, Medical specialties, Vaccine, Virology, Medicine, Vaccines, Clinical medicine, COVID-19 vaccine

An escalated process of delivering a regulated vaccine to market has spearheaded a fast race by manufacturers to present a successful solution to the pandemic.

Key Points: 
  • An escalated process of delivering a regulated vaccine to market has spearheaded a fast race by manufacturers to present a successful solution to the pandemic.
  • Supply chain challenges are evident as more information becomes available about a viable vaccine.
  • Crane Worldwide has documented, tested, verified, and validated to the most rigorous requirements that are known about the vaccine.
  • It is our moral duty, as a 3PL partner, to ensure that we have solid solutions in place when the vaccine is released.

Crane Worldwide strengthens its global solutions for the safe delivery of the COVID-19 vaccine

Retrieved on: 
Tuesday, November 17, 2020
Vaccination, Medical specialties, Vaccine, Virology, Medicine, Vaccines, Clinical medicine, COVID-19 vaccine

An escalated process of delivering a regulated vaccine to market has spearheaded a fast race by manufacturers to present a successful solution to the pandemic.

Key Points: 
  • An escalated process of delivering a regulated vaccine to market has spearheaded a fast race by manufacturers to present a successful solution to the pandemic.
  • Supply chain challenges are evident as more information becomes available about a viable vaccine.
  • Crane Worldwide has documented, tested, verified, and validated to the most rigorous requirements that are known about the vaccine.
  • It is our moral duty, as a 3PL partner, to ensure that we have solid solutions in place when the vaccine is released.

DGAP-News: CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Retrieved on: 
Tuesday, November 17, 2020
CureVac, Tübingen, Medicine, Health, Medical research, COVID-19 vaccine, CVac, Vaccines, Ingmar Hoerr

CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV
    TBINGEN, Germany/ BOSTON, USA - November 17, 2020 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that it is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV.
  • CureVac aims to build a broad and integrated European vaccine manufacturing network with highly experienced CDMO (Contract Development and Manufacturing Organization) partners for each of the key manufacturing steps for CVnCoV.
  • CureVac's CVnCoV manufacturing network will leverage expertise and capacity across Germany, France, the Netherlands, Belgium, Spain and Austria, as well as potentially Sweden, Poland, Italy and Ireland.

Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence

Retrieved on: 
Monday, November 16, 2020
Medicine, Clinical medicine, Medical specialties, Vaccination, Vaccines, Cancer vaccines, Cancer vaccine, Vaccine, Melanoma, Oncophage, Herpes simplex research

These results are important because most cancer vaccine trials have failed to show clinical efficacy.

Key Points: 
  • These results are important because most cancer vaccine trials have failed to show clinical efficacy.
  • Sixty patients who had stage 2 or 3 melanoma, and whose cancer was successfully removed via surgery, received the vaccine.
  • Half of the patients received the vaccine alone while the other half received the vaccine with Flt3L and poly-ICLC.
  • Researchers also plan to follow trial participants over time and measure how many have cancer recurrence to further study the vaccine's efficacy in each group.

DGAP-News: CureVac : European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

Retrieved on: 
Monday, November 16, 2020
Medical research, Medicine, Health sciences, Health care, COVID-19 vaccine, Vaccines, CureVac, Vaccine, CVnCoV, CureVac

CureVac : European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac : European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • The mRNA vaccine will be supplied once it has proven to be safe and effective against COVID-19.
  • "As an important step toward that goal, we are proud to potentially supply our COVID-19 vaccine to citizens of the European Union.
  • Vaccine doses are expected to be produced both at CureVac's in-house, GMP-certified manufacturing site in Germany and across a broad European manufacturing network.

Stop & Shop Will Be Among the First Retailers to Administer Future COVID-19 Vaccines, Once Approved and Available

Retrieved on: 
Monday, November 16, 2020
Retailers, Retailing, Medical specialties, Influenza vaccine, Vaccines, Vaccine, Stop & Shop, Grocery store

The vaccine will be administered to Stop & Shop customers at no cost.

Key Points: 
  • The vaccine will be administered to Stop & Shop customers at no cost.
  • Flu shots are currently available at all Stop & Shops pharmacy locations, and Stop & Shop is taking extensive health and safety precautions in accordance with CDC guidelines.
  • A neighborhood grocer for more than 100 years, todays Stop & Shop is refreshed, reenergized and inspired, delivering new conveniences for customers.
  • To learn more about Stop & Shop, visit stopandshop.com .

Vaxart Hosting Key Opinion Leader Panel Call for Investors

Retrieved on: 
Monday, November 16, 2020
Medical research, Life sciences, Medicine, Health sciences, Vaccines, Virology, Vaccination, Vaxart, Vaccine, COVID-19 vaccine

Dr. Pepper on the importance of immunological memory and quick responses to a pathogen, and how it relates to COVID-19.

Key Points: 
  • Dr. Pepper on the importance of immunological memory and quick responses to a pathogen, and how it relates to COVID-19.
  • Dr. Sean Tucker, Ph.D. (Vaxart) to discuss VXA-CoV2-1, Vaxarts oral investigational tablet COVID-19 vaccine.
  • Both KOLs and the Vaxart management team will be available for Q&A following the formal presentation.
  • Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.